Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Clin Cancer Res. 2016 Jun 22;22(24):6118–6128. doi: 10.1158/1078-0432.CCR-15-3099

Figure 3.

Figure 3

Pacritinib inhibits CSF-1R. (A) Monocytes were treated (5 minutes) with recombinant human CSF-1 (10 ng/mL) in the presence of ruxolitinib (5 μM), fedratinib (5 μM), pacritinib (1 μM) or vehicle control (DMSO). Total and phosphorylated CSF-1R was detected in cell lysates by sandwich ELISA (in triplicate). The ratio of phosphorylated:total CSF-1R is shown. (B,C) Phosphorylation of the CSF-1R targets indicated was examined by immunoblotting (B) or flow cytometry (C).